Furthermore, a Phase 3 clinical trial is ongoing using a combination of various anti-oxidants to treat FXS patients (NCT02942498), as suggested the fact that SOD1 is less expressed in mouse Fmr1-KO cells (Bechara et al., 2009) and, consequently, markers of oxidative stress have been described in brain of infant and adult Fmr1-null mice (El Bekay et al., 2007; de Diego-Otero et al., 2009; Davidovic et al., 2011). The gene discussed is FMR1; the disease is fragile X syndrome.